Skip to main content

Advertisement

SpringerLink
Log in

The effects of hyperprolactinemia on bone and fat

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Many patients with prolactin secreting pituitary tumors have decreased bone mineral. The bone loss is associated with an increase in bone resorption and is secondary to prolactin-induced hypogonadism. In both sexes trabecular bone in the spine and hip is more affected than cortical bone in the distal radius. Normalization of prolactin and restoration of gonadal function increases bone density but is not associated with normalization of bone mass. It is not known whether the bone loss in hyperprolactinemic subjects represents a failure to achieve peak bone mass or is due to accelerated bone loss. Despite low bone density hyperprolactinemic subjects do not demonstrate increased fractures. The association between prolactin, weight gain and obesity suggests that prolactin may also be a modulator of body composition and body weight. It is not known whether hyperprolactinemia associated weight gain is due to stimulation of lipogenesis or due to disruption of central nervous system dopaminergic tone. Hyperprolactinemia is also associated with insulin resistance and endothelial dysfunction which may improve after normalization of prolactin. The clinical significance of these findings and the precise role of prolactin in regulation of weight and metabolism remain to be elucidated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Harris J, Stanford PM, Oakes SR, Ormandy CJ (2004) Prolactin and the prolactin receptor: new targets of an old hormone. Ann Med 36:414–425, Medline. doi:10.1080/07853890410033892

    Article  PubMed  CAS  Google Scholar 

  2. Goffin V, Binart N, Touraine P, Kelly PA (2002) Prolactin: the new biology of an old hormone. Annu Rev Physiol 64:47–67, Medline. doi:10.1146/annurev.physiol.64.081501.131049

    Article  PubMed  CAS  Google Scholar 

  3. Klibanski A, Neer RM, Beitins IZ, Ridgway EC, Zervas NT, McArthur JW (1980) Decreased bone density in hyperprolactinemic women. N Engl J Med 303:1511–1514, Medline

    Article  PubMed  CAS  Google Scholar 

  4. Schlechte JA, Sherman B, Martin R (1983) Bone density in amenorrheic women with and without hyperprolactinemia. J Clin Endocrinol Metab 56:1120–1123, Medline

    PubMed  CAS  Google Scholar 

  5. Koppelman MC, Kurtz DW, Morrish KA et al (1984) Vertebral body bone mineral content in hyperprolactinemic women. J Clin Endocrinol Metab 59:1050–1053, Medline

    PubMed  CAS  Google Scholar 

  6. Cann CE, Martin MC, Genant HK, Jaffe RB (1984) Decreased spinal mineral content in amenorrheic women. JAMA 251:626–629, Medline. doi:10.1001/jama.251.5.626

    Article  PubMed  CAS  Google Scholar 

  7. Caraceni MP, Corghi E, Ortolani S, Casazza S, D’Alberton A, Motta T (1985) Increased forearm bone mineral content after bromocriptine treatment in hyperprolactinemia. Calcif Tissue Int 37:687–689, Medline. doi:10.1007/BF02554932

    Article  PubMed  CAS  Google Scholar 

  8. Klibanski A, Greenspan SL (1986) Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med 315:542–546, Medline

    Article  PubMed  CAS  Google Scholar 

  9. Greenspan SL, Neer RM, Ridgway EC, Klibanski A (1986) Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med 104:777–782, Medline

    PubMed  CAS  Google Scholar 

  10. Schlechte J, el-Khoury G, Kathol M, Walkner L (1987) Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 64:1021–1026, Medline

    PubMed  CAS  Google Scholar 

  11. Ciccarelli E, Savino L, Carlevatto V, Bertagna A, Isaia GC, Camanni F (1988) Vertebral bone density in non-amenorrhoeic hyperprolactinaemic women. Clin Endocrinol (Oxf) 28:1–6

    Google Scholar 

  12. Nyström E, Leman J, Lundberg PA et al (1988) Bone mineral content in normally menstruating women with hyperprolactinaemia. Horm Res 29:214–217, Medline

    Article  PubMed  Google Scholar 

  13. Klibanski A, Biller BM, Rosenthal DI, Schoenfeld DA, Saxe V (1988) Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 67:124–130, Medline

    PubMed  CAS  Google Scholar 

  14. Greenspan SL, Oppenheim DS, Klibanski A (1989) Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 110:526–531, Medline

    PubMed  CAS  Google Scholar 

  15. Sartorio A, Conti A, Ambrosi B, Muratori M, Morabito F, Faglia G (1990) Osteocalcin levels in patients with microprolactinoma before and during medical treatment. J Endocrinol Invest 13:419–422, Medline

    PubMed  CAS  Google Scholar 

  16. Biller BM, Baum HB, Rosenthal DI, Saxe VC, Charpie PM, Klibanski A (1992) Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 75:692–697, Medline. doi:10.1210/jc.75.3.692

    Article  PubMed  CAS  Google Scholar 

  17. Schlechte J, Walkner L, Kathol M (1992) A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia. J Clin Endocrinol Metab 75:698–703, Medline. doi:10.1210/jc.75.3.698

    Article  PubMed  CAS  Google Scholar 

  18. Kayath MJ, Lengyel AM, Vieira JG (1993) Prevalence and magnitude of osteopenia in patients with prolactinoma. Braz J Med Biol Res 26:933–941, Medline

    PubMed  CAS  Google Scholar 

  19. Di Somma C, Colao A, Di Sarno A et al (1998) Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 83:807–813, Medline. doi:10.1210/jc.83.3.807

    Article  PubMed  CAS  Google Scholar 

  20. Shaarawy M, El-Dawakhly AS, Mosaad M, El-Sadek MM (1999) Biomarkers of bone turnover and bone mineral density in hyperprolactinemic amenorrheic women. Clin Chem Lab Med 37:433–438, Medline. doi:10.1515/CCLM.1999.071

    Article  PubMed  CAS  Google Scholar 

  21. Colao A, Di Somma C, Loche S, Di Sarno A, Klain M, Pivonello R, Pietrosante M, Salvatore M, Lombardi G (2000) Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol (Oxf) 52:319–327

    Google Scholar 

  22. Naliato EC, Farias ML, Braucks GR, Costa FS, Zylberberg D, Violante AH (2005) Prevalence of osteopenia in men with prolactinoma. J Endocrinol Invest 28:12–17, Medline

    PubMed  CAS  Google Scholar 

  23. Naliato EC, Violante AH, Caldas D et al (2008) Bone density in women with prolactinoma treated with dopamine agonists. Pituitary 11:21–28, Medline. doi:10.1007/s11102-007-0064-4

    Article  PubMed  CAS  Google Scholar 

  24. Bikle DD, Spencer EM, Burke WH, Rost CR (1980) Prolactin but not growth hormone stimulates 1,25-dihydroxyvitamin D3 production by chick renal preparations in vitro. Endocrinology 107:81–84, Medline

    PubMed  CAS  Google Scholar 

  25. Spanos E, Colston KW, Evans IM, Galante LS, Macauley SJ, Macintyre I (1976) Effect of prolactin on vitamin D metabolism. Mol Cell Endocrinol 5:163–167, Medline. doi:10.1016/0303-7207(76)90080-0

    Article  PubMed  CAS  Google Scholar 

  26. Pahuja DN, DeLuca HF (1981) Stimulation of intestinal calcium transport and bone calcium mobilization by prolactin in vitamin D-deficient rats. Science 214:1038–1039, Medline. doi:10.1126/science.7302575

    Article  PubMed  CAS  Google Scholar 

  27. Charoenphandhu N, Krishnamra N (2007) Prolactin is an important regulator of intestinal calcium transport. Can J Physiol Pharmacol 85:569–581, Medline. doi:10.1139/Y07-041

    Article  PubMed  CAS  Google Scholar 

  28. Kumar R, Abboud CF, Riggs BL (1980) The effect of elevated prolactin levels on plasma 1,25-dihydroxyvitamin D and intestinal absorption of calcium. Mayo Clin Proc 55:51–53, Medline

    PubMed  CAS  Google Scholar 

  29. Adams ND, Garthwaite TL, Gray RW, Hagen TC, Lemann J Jr (1979) The interrelationships among prolactin, 1,25-dihydroxyvitamin D, and parathyroid hormone in humans. J Clin Endocrinol Metab 49:628–630, Medline

    PubMed  CAS  Google Scholar 

  30. Brown DJ, Spanos E, MacIntyre I (1980) Role of pituitary hormones in regulating renal vitamin D metabolism in man. BMJ 280:277–278, Medline

    Article  PubMed  CAS  Google Scholar 

  31. Genant HK, Cann CE, Ettinger B, Gordon GS (1982) Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med 97:699–705, Medline

    PubMed  CAS  Google Scholar 

  32. Steinberg KK, Freni-Titulaer LW, DePuey EG et al (1989) Sex steroids and bone density in premenopausal and perimenopausal women. J Clin Endocrinol Metab 69:533–539, Medline

    PubMed  CAS  Google Scholar 

  33. Warren MP, Brooks-Gunn J, Fox RP, Lancelot C, Newman D, Hamilton WG (1991) Lack of bone accretion and amenorrhea: evidence for a relative osteopenia in weight bearing bones. J Clin Endocrinol Metab 72:847–853, Medline

    PubMed  CAS  Google Scholar 

  34. Biller BM, Coughlin JF, Saxe V, Schoenfeld D, Spratt DI, Klibanski A (1991) Osteopenia in women with hypothalamic amenorrhea: a prospective study. Obstet Gynecol 78:996–1001, Medline

    PubMed  CAS  Google Scholar 

  35. Bachrach LK, Katzman DK, Litt IF, Guido D, Marcus R (1991) Recovery from osteopenia in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 72:602–606, Medline

    PubMed  CAS  Google Scholar 

  36. do Carmo I, Mascarenhas M, Macedo A et al (2007) A study of bone density change in patients with anorexia nervosa. Eur Eat Disord Rev 15:457–462, Medline. doi:10.1002/erv.812

    Article  PubMed  Google Scholar 

  37. Castelo-Branco C, Rovira M, Pons F et al (1996) The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation. Maturitas 23:307–312, Medline. doi:10.1016/0378-5122(95)00991-4

    Article  PubMed  CAS  Google Scholar 

  38. Prior JC, Vigna YM, Wark JD et al (1997) Premenopausal ovariectomy-related bone loss: a randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate. J Bone Miner Res 12:1851–1863, Medline. doi:10.1359/jbmr.1997.12.11.1851

    Article  PubMed  CAS  Google Scholar 

  39. Moore BJ, Gerardo-Gettens T, Horwitz BA, Stern JS (1986) Hyperprolactinemia stimulates food intake in the female rat. Brain Res Bull 17:563–569, Medline. doi:10.1016/0361-9230(86)90226-1

    Article  PubMed  CAS  Google Scholar 

  40. Byatt JC, Staten NR, Salsgiver WJ, Kostelc JG, Collier RJ (1993) Stimulation of food intake and weight gain in mature female rats by bovine prolactin and bovine growth hormone. Am J Physiol (Endocrinol Metab. 27) 264:E986–E992

    Google Scholar 

  41. Galluzi F, Salti R, Stagi S, La Cauza F, Chiarelli F (2005) Reversible weight gain and prolactin levels—long-term follow-up in childhood. J Pediatr Endocrinol Metab 18:921–924, Medline

    Google Scholar 

  42. Creemers LB, Zelissen PM, van’t Verlaat JW, Koppeschaar HP (1991) Prolactinoma and body weight: a retrospective study. Acta Endocrinol (Copenh) 125:392–396

    Google Scholar 

  43. Kok P, Roelfsema F, Frölich M, Meinders E, Pijl H (2004) Prolactin release is enhanced in proportion to excess visceral fat in obese women. J Clin Endocrinol Metab 89:4445–4449, Medline. doi:10.1210/jc.2003-032184

    Article  PubMed  CAS  Google Scholar 

  44. Doknic M, Pekic S, Zarkovic M et al (2002) Dopaminergic tone and obesity: and insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 147:77–84, Medline. doi:10.1530/eje.0.1470077

    Article  PubMed  CAS  Google Scholar 

  45. Greenman Y, Tordijman K, Stern N (1998) Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf) 48:547–553, Medline. doi:10.1046/j.1365-2265.1998.00403.x

    Article  CAS  Google Scholar 

  46. Ferreira MF, Sobrinho LG, Santos MA, Sousa MFF, Uvnäs-Moberg K (1998) Rapid weight gain, at least in some women, is an expression of a neuroendocrine state characterized by reduced hypothalamic dopaminergic tone. Psychoneuroendocrinology 23:1005–1013, Medline. doi:10.1016/S0306-4530(98)00063-8

    Article  PubMed  CAS  Google Scholar 

  47. Schmid C, Goede DL, Hauser RS, Brändle M (2006) Increased prevalence of high body mass index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly 138:254–258

    Google Scholar 

  48. Ferreira MF, Sobrinho LG, Pires JS, Silva MES, Santos MA, Sousa MFF (1995) Endocrine and psychological evaluation of women with recent weight gain. Psychoneuroendocrinology 20:53–63, Medline. doi:10.1016/0306-4530(94)E0041-7

    Article  PubMed  CAS  Google Scholar 

  49. Wallace RB, Sherman BM, Bean JA (1985) Clinical and biologic antecedents of the amenorrhea/hyperprolactinemia syndrome: a case control study. Fertil Steril 43:726–732, Medline

    PubMed  CAS  Google Scholar 

  50. Wang DY, De Stavola BL, Bulbrook RD et al (1987) The relationship between blood prolactin levels and risk of breast cancer in premenopausal women. Eur J Clin Oncol 23:1541–1548. doi:10.1016/0277-5379(87)90098-8

    Article  CAS  Google Scholar 

  51. Martel P, Fantino M (1996) Mesolimbic dopaminergic system activity as a function of food reward: a microdialysis study. Pharmacol Biochem Behav 53:221–226, Medline. doi:10.1016/0091-3057(95)00187-5

    Article  PubMed  CAS  Google Scholar 

  52. Balcioglu A, Wurtman RJ (1998) Effects of phentermine on striatal dopamine and serotonin release in conscious rats: in vivo microdialysis study. Int J Obes Relat Metab Disord 22:325–328, Medline. doi:10.1038/sj.ijo.0800589

    Article  PubMed  CAS  Google Scholar 

  53. Wang GJ, Volkow ND, Logan J et al (2001) Brain dopamine and obesity. Lancet 357:354–357, Medline. doi:10.1016/S0140-6736(00)03643-6

    Article  PubMed  CAS  Google Scholar 

  54. Kopelman PG, White N, Pilkington TRE, Jeffcoate SL (1979) Impaired hypothalamic control of prolactin secretion in massive obesity. Lancet 1:747–750, Medline. doi:10.1016/S0140-6736(79)91206-6

    Article  PubMed  CAS  Google Scholar 

  55. Cavagnini F, Maraschini C, Pinto M, Dubini A, Polli EE (1981) Impaired prolactin secretion in obese patients. J Endocrinol Invest 4:149–153, Medline

    PubMed  CAS  Google Scholar 

  56. Amatruda JM, Hochstein M, Hsu TH, Lockwood DH (1982) Hypothalamic and pituitary dysfunction in obese males. Int J Obes 6:183–189, Medline

    PubMed  CAS  Google Scholar 

  57. Weaver JU, Noonan K, Kopelman PG, Coste M (1990) Impaired prolactin secretion and body fat distribution in obesity. Clin Endocrinol (Oxf) 32:641–646, Medline

    Article  CAS  Google Scholar 

  58. Weaver JU, Noonan K, Kopelman PG (1991) An association between hypothalamic–pituitary dysfunction and peripheral endocrine function in extreme obesity. Clin Endocrinol (Oxf) 35:97–102, Medline

    Article  CAS  Google Scholar 

  59. Röjdmark S, Rössner S (1991) Decreased dopaminergic control of prolactin secreation in male obesity: normalization by fasting. Metabolism 40:191–195, Medline. doi:10.1016/0026-0495(91)90173-T

    Article  PubMed  Google Scholar 

  60. Kopelman PG, Pilkington TRE, White N, Jeffcoate SL (1980) Persistence of abnormal hypothalamic control of prolactin secretion in some obese women after weight reduction. BMJ 281:358–359, Medline

    Article  PubMed  CAS  Google Scholar 

  61. Ben-Jonathan N, Hnasko R (2001) Dopamine as a prolactin (PRL] inhibitor. Endocr Rev 22:724–763, Medline. doi:10.1210/er.22.6.724

    Article  PubMed  CAS  Google Scholar 

  62. Baptista T, Alastre T, Contreras Q et al (1997) Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy men: relationship with body weight regulation. Pharmacopsychiatry 30:250–255, Medline

    Article  PubMed  CAS  Google Scholar 

  63. Baptista T, Lacruz A, Meza T et al (2001) Antipsychotic drugs and obesity: is prolactin involved? Can J Psychiatry 46:829–834, Medline

    PubMed  CAS  Google Scholar 

  64. Baptista T, Parada M, Hernandez L (1987) Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved? Pharmacol Biochem Behav 27:399–405, Medline. doi:10.1016/0091-3057(87)90340-6

    Article  CAS  Google Scholar 

  65. Ling C, Svensson L, Odén B et al (2003) Identification of functional prolactin (PRL] gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab 88:1804–1808, Medline. doi:10.1210/jc.2002-021137

    Article  PubMed  CAS  Google Scholar 

  66. Hugo ER, Brandebourg TD, Comstock CES, Gersin KS, Sussman JJ, Ben-Jonathan N (2006) LS14: a novel human adipocyte cell line that produces prolactin. Endocrinology 147:306–313, Medline. doi:10.1210/en.2005-0989

    Article  PubMed  CAS  Google Scholar 

  67. Highman TJ, Friedman JE, Huston LP, Wong WW, Catalano PM (1998) Longitudinal changes in maternal serum leptin concentrations, body composition, and resting metabolic rate in pregnancy. Am J Obstet Gynecol 178:1010–1015, Medline. doi:10.1016/S0002-9378(98)70540-X

    Article  PubMed  CAS  Google Scholar 

  68. Butte NF, Hopkinson JM, Nicolson MA (1997) Leptin in human reproduction: serum leptin levels in pregnant and lactating women. J Clin Endocrinol Metab 82:585–589, Medline. doi:10.1210/jc.82.2.585

    Article  PubMed  CAS  Google Scholar 

  69. Mukherjea R, Castonguay TW, Douglass LW, Moser-Veillon P (1999) Elevated leptin concentrations in pregnancy and lactation: possible role as a modulator of substrate utilization. Life Sci 65:1183–1193, Medline. doi:10.1016/S0024-3205(99)00352-5

    Article  PubMed  CAS  Google Scholar 

  70. Landgraf R, Landraf-Leurs MM, Weissmann A, Hörl R, von Werder K, Scriba PC (1977) Prolactin: a diabetogenic hormone. Diabetologia 13:99–104, Medline. doi:10.1007/BF00745135

    Article  PubMed  CAS  Google Scholar 

  71. Pelkonen R, Nikkilä EA, Grahne B (1982) Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma. Clin Endocrinol (Oxf) 16:383–390, Medline

    Article  CAS  Google Scholar 

  72. Schernthaner G, Prager R, Punzengruber C, Luger A (1985) Severe hyperprolactinemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia 28:138–142, Medline

    PubMed  CAS  Google Scholar 

  73. Foss MC, Paula FJ, Paccola GM, Piccinato CE (1995) Peripheral glucose metabolism in human hyperprolactinemia. Clin Endocrinol (Oxf) 43:721–726, Medline

    Article  CAS  Google Scholar 

  74. Gustafson AB, Banasiak MF, Kalkhoff RK, Hagen TC, Kim HJ (1980) Correlation of hyperprolactinemia with altered plasma insulin and glucagon: similarity to effects of late human pregnancy. J Clin Endocrinol Metab 51:242–246, Medline

    Article  PubMed  CAS  Google Scholar 

  75. Serri O, Beauregard H, Rasio E, Hardy J (1986) Decreased sensitivity to insulin in women with microprolactinomas. Fertil Steril 45:572–574, Medline

    PubMed  CAS  Google Scholar 

  76. Tuzcu A, Bahceci M, Dursun M, Turgut C, Bahceci S (2003) Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest 26:341–346, Medline

    PubMed  CAS  Google Scholar 

  77. Serri O, Ling L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G (2006) The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf) 64:366–370, Medline

    CAS  Google Scholar 

  78. Asai-Sato M, Okamoto M, Endo M, et al (2006) Hypoadiponectinemmia in lean lactating women: prolactin inhibits adiponectin secretion from human adipocytes. Endocr J 53:555–562. Medline. doi:10.1507/endocrj.K06-026

    Article  PubMed  CAS  Google Scholar 

  79. Nilsson L, Binart N, Bohlooly-Y M, et al (2005) Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun 331:1120–1126, Medline. doi:10.1016/j.bbrc.2005.04.026

    Article  PubMed  CAS  Google Scholar 

  80. Fuglsang J, Skjærbæk C, Frystyk J, Flyvbjerg A, Ovesen P (2006) A longitudinal study of serum adiponectin during normal pregnancy. BJOG 113:110–113, Medline. doi:10.1111/j.1471-0528.2005.00792.x

    Article  PubMed  CAS  Google Scholar 

  81. Yavuz D, Deyneli O, Akpinar I, et al (2003) Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol 149:187–193, Medline. doi:10.1530/eje.0.1490187

    Article  PubMed  CAS  Google Scholar 

  82. Khosla S, Atkinson EJ, Dunstan CR, O’Fallon WM (2002) Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 87:1550–1554, Medline. doi:10.1210/jc.87.4.1550

    Article  PubMed  CAS  Google Scholar 

  83. Yialamas MA, Dwyer AA, Hanley E, Lee H, Pitteloud N, Hayes FJ (2007) Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 92:4254–4259, Medline. doi:10.1210/jc.2007-0454

    Article  PubMed  CAS  Google Scholar 

  84. Soran H, Wilding J, MacFarlane I (2004) Body weight and prolactinoma: a retrospective study. Int J Obes 28:183, doi:10.1038/sj.ijo.0802492

    Article  CAS  Google Scholar 

  85. Yermus R, Ezzat S (2002) Does normalization of prolactin levels result in weight loss in patients with prolactin secreting pituitary adenomas? Clin Endocrinol (Oxf) 56:562, Medline. doi:10.1046/j.1365-2265.2002.01510.x

    Article  CAS  Google Scholar 

  86. Delgrange E, Donckier J, Maiter D (1999) Hyperprolactinemia as a reversible cause of weight gain in male patients? Clin Endocrinol (Oxf) 50:271–272, Medline. doi:10.1046/j.1365-2265.1999.00700.x

    Article  CAS  Google Scholar 

  87. Cincotta AH, Meier AH (1989) Reductions of body fat stores and total plasma cholesterol and triglyceride concentrations in several species by bromocriptine treatment. Life Sci 45:2247–2254, Medline. doi:10.1016/0024-3205(89)90066-0

    Article  PubMed  CAS  Google Scholar 

  88. Meier AH, Cincotta AH, Lovell WC (1992) Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics. Experientia 48:248–253, Medline. doi:10.1007/BF01930467

    Article  PubMed  CAS  Google Scholar 

  89. Cincotta AH, Meier AH (1996) Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 19:667–670, Medline. doi:10.2337/diacare.19.6.667

    Article  PubMed  CAS  Google Scholar 

  90. Kamath V, Jones CN, Yip JC et al (1997) Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose. Insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemia women. Diabetes Care 20:1697–1701, Medline. doi:10.2337/diacare.20.11.1697

    CAS  Google Scholar 

  91. Wasada T, Kawahara R, Iwamoto Y (2000) Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients. Diabetes Care 23:1039–1040, Medline. doi:10.2337/diacare.23.7.1039

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, 52242, USA

    Amal Shibli-Rahhal & Janet Schlechte

Authors
  1. Amal Shibli-Rahhal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Janet Schlechte
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Janet Schlechte.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shibli-Rahhal, A., Schlechte, J. The effects of hyperprolactinemia on bone and fat. Pituitary 12, 96–104 (2009). https://doi.org/10.1007/s11102-008-0097-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-008-0097-3

Keywords

Search

Navigation